Congratulations to Dr Mohamed Saad, who has been awarded a Cancer Council Victoria (CCV) Postdoctoral Cancer Research Fellowship to inform the design of better treatment approaches in lung cancer.
Dr Saad, of the Cancer and Immune Signalling Laboratory in the Centre for Innate Immunity and Infectious Diseases at Hudson Institute, was awarded $77,950 for his one-year research project to delve into how an enzyme promotes lung cancer.
The Postdoctoral Fellowships are offered by CCV to provide Victorian scientists who have recently completed a PhD with support for up to one year of research based on their thesis work—a natural progression of the project.
“During my PhD, our team identified the enzyme ADAM17 as a therapeutic target for lung cancer,” said Dr Saad.
“We have shown that ADAM17 promotes lung cancer through the activation of inflammatory signalling pathways; however, inhibition of ADAM17 activity resulted in greater suppression of tumour burden compared to the blocking of these inflammatory pathways. Therefore, we strongly suggest that ADAM17 processes additional, as yet unknown, substances which could be implicated in lung cancer progression.”
“The CCV fellowship is giving me the opportunity to build upon my recent PhD findings and use state-of-the-art proteomics techniques to reveal ADAM17-regulated processes, through which lung cancer could be better treated and diagnosed.”